Metastatic Breast Cancer
Conditions
Brief summary
The purpose of this study is to identify the highest tolerable dose of pyrotinib in combination with vinorelbine and to assess the safety and efficacy of the combination in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer. The study will be conducted in two parts. In the first part, testing will be done on up to 12 subjects to determine the highest tolerable dose of pyrotinib and vinorelbine in patients with advanced solid tumors. In the second part of the study, we will compare the safety and efficacy of Pyrotinib + vinorelbine vs. Treatment of Physician's Choice in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy.Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination.
Interventions
DRUGPyrotinib
Pyrotinib Maleate combine with vinorelbine as the second-line treatment to HER2-positive Metastatic Breast Cancer
The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for second-line HER2-positive metastatic breast cancer treatment after receipt of trastuzumab-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
DRUGvinorelbine
vinorelbine
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* HER2 status must be prospectively, centrally tested and be HER2-positive based on central laboratory assay results * Histologically or cytologically confirmed invasive breast cancer * Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both a taxane, alone or in combination with another agent, and trastuzumab, alone or in combination with another agent * Documented progression (which occur during or after most recent treatment or within 6 months after completing of adjuvant therapy) of incurable, unresectable, locally advanced or metastatic breast cancer, defined by the investigator * Measurable and/or nonmeasurable disease; participants with central nervous system-only disease are excluded * Cardiac ejection fraction greater than or equal to (\>/=) 50 percent (%) by either echocardiogram or multi-gated acquisition scan * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion criteria
* History of treatment with pyrotinib * Prior treatment with lapatinib or neratinib * History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma * History of receiving any anti-cancer drug/biologic or investigational treatment within 28 days prior to randomization except hormone therapy * Recovery of treatment-related toxicity consistent with other eligibility criteria * History of radiation therapy within 28 days of randomization * Brain metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as any history of radiation, surgery, or other therapy, including steroids, to control symptoms from brain metastases within 2 months (60 days) of randomization * History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment * History of myocardial infarction or unstable angina * Current severe, uncontrolled systemic disease (for example, clinically significant cardiovascular, pulmonary, or metabolic disease) * Pregnancy or lactation * Current known active infection with human immunodeficiency virus (HIV) or hepatitis C virus * Presence of conditions that could affect gastrointestinal absorption: Malabsorption syndrome, resection of the small bowel or stomach, and ulcerative colitis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| maximum-tolerated dose (MTD) | 42 days | The maximum-tolerated dose (MTD) will be defined as the maximum dose level at which no more than one subject out of three experiences has a dose-limiting toxicity (DLT) upon completing two treatment cycle. |
| PFS as Assessed by the Investigator | From enrollment to progression or death (for any reason),assessed up to 100 months | progression-free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | from enrollment to progression or death (for any reason), assessed up to 100 months | CR+PR |
| OS | from enrollment to death (for any reason).assessed up to 100 months | OS was defined as the time from the date of randomization to the date of death from any cause |
Outcome results
None listed